← Back to Search

EM Tracking Devices for Biopsy Accuracy in Kidney and Prostate Cancer

N/A
Waitlist Available
Led By Bradford J Wood, M.D.
Research Sponsored by National Institutes of Health Clinical Center (CC)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age greater than or equal to 18 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is exploring whether a new tracking device can help place needles more accurately during biopsy or ablation procedures.

Who is the study for?
Adults over 18 needing a biopsy or ablation guided by CT, with lesions hard to locate using standard imaging. They must understand and agree to the study's terms, be able to lie still during the procedure, and not have severe illnesses affecting decision-making. Excluded are those over 606 pounds, unable to hold their breath if needed, mentally unable to consent, or with pacemakers/electrical implants.Check my eligibility
What is being tested?
The trial is testing an experimental 'smart needle' equipped with a tracking device for better accuracy in locating hard-to-find abnormalities during invasive procedures like biopsies. It works like mini GPS inside the body using weak magnets and aims to improve needle placement.See study design
What are the potential side effects?
Potential side effects aren't specified but may include typical risks associated with invasive procedures such as pain at the insertion site, bleeding, infection risk from needles used in biopsies or ablations, and possible allergic reactions to materials used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of using electromagnetic devices in different cohorts.
Secondary outcome measures
Success of ablation as determined by imaging

Trial Design

1Treatment groups
Experimental Treatment
Group I: All cohorts (prostate biopsy percutaneous biopsy and ablation)Experimental Treatment1 Intervention
This study will consist of comparison of tracked imaging with near-simultaneous actual imaging .

Find a Location

Who is running the clinical trial?

National Institutes of Health Clinical Center (CC)Lead Sponsor
383 Previous Clinical Trials
985,097 Total Patients Enrolled
4 Trials studying Prostate Cancer
177 Patients Enrolled for Prostate Cancer
Bradford J Wood, M.D.Principal InvestigatorNational Institutes of Health Clinical Center (CC)
7 Previous Clinical Trials
184 Total Patients Enrolled
1 Trials studying Prostate Cancer
14 Patients Enrolled for Prostate Cancer

Media Library

EM Tracking Clinical Trial Eligibility Overview. Trial Name: NCT00102544 — N/A
Prostate Cancer Research Study Groups: All cohorts (prostate biopsy percutaneous biopsy and ablation)
Prostate Cancer Clinical Trial 2023: EM Tracking Highlights & Side Effects. Trial Name: NCT00102544 — N/A
EM Tracking 2023 Treatment Timeline for Medical Study. Trial Name: NCT00102544 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for participants to join the trial?

"According to the clinicaltrials.gov website, this research trial is not presently taking on any additional candidates. It was first posted on February 23rd 2005 and most recently updated November 1st 2022; however, there are over two-thousand three hundred other studies actively recruiting right now."

Answered by AI
Recent research and studies
~131 spots leftby Dec 2024